HIPRA, with 50 years of experience fighting communicable diseases through vaccine development, is a company committed to health, people, society and progress. This is why, in such an exceptional situation, HIPRA has decided to provide its know-how to tackle the pandemic.
The HIPRA Covid-19 vaccine and its characteristics
The active component of the HIPRA Covid-19 VACCINE is an heterologous recombinant heterodimer protein that emulates the spike (S) protein and includes sequences of the new variants of the SARS-CoV-2 virus. The antigen, which is the active component of the vaccine, requires an adjuvant to amplify and enhance the immune response. In the HIPRA Covid-19 vaccine, the adjuvant is an oil-in-water emulsion, which has already demonstrated its efficacy and safety in many other vaccines.
This combination is capable of generating a strong immune response against the S protein of the SARS-CoV-2 virus, and consequently protecting against Covid-19.
The HIPRA vaccine is stored between 2 and 8º C, which facilitates its logistics and distribution. It is a ready-to-use vaccine administered via the intramuscular route.